Immunotherapy Advances in RRMM: An Educational Journey

Multiple myeloma has become the most common hematologic malignancy in the United States adult population with over 120,000 people living with the disease. Despite new and more effective treatments, multiple myeloma, unfortunately, remains largely incurable with relapse and disease progression still common.

Dr. Ola Landgren Chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Cornell Medical College discusses advances in the field of immunotherapy for relapsed refractory multiple myeloma (RRMM). He discusses different treatment modalities and their unique strengths and limitations which have shown high antimyeloma activity that may address a critical unmet need in heavily pretreated and refractory patients. Dr. Landgren indicates that future studies will help identify optimal combinations and sequencing of different immunotherapies